Terms: = Pancreatic cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
108 results:
1. Anti-tumorigenic effects of naive and TLR4-primed adipose-derived mesenchymal stem cells on pancreatic ductal adenocarcinoma cells.
Kaçaroğlu D; Yaylacı S; Gurbuz N
Cancer Med; 2024 Jan; 13(2):e6964. PubMed ID: 38379331
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
3. A SIRT6 Inhibitor, Marine-Derived Pyrrole-Pyridinimidazole Derivative 8a, Suppresses Angiogenesis.
Song N; Tang Y; Wang Y; Guan X; Yu W; Jiang T; Lu L; Gu Y
Mar Drugs; 2023 Sep; 21(10):. PubMed ID: 37888452
[TBL] [Abstract] [Full Text] [Related]
4. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
[TBL] [Abstract] [Full Text] [Related]
5. [Apatinib Suppressed Macrophage-Mediated Malignant Behavior of Hepatocellular Carcinoma Cells via Modulation of vegfr2/STAT3/PD-L1 Signaling].
Yin T; Fu CB; Wu DD; Nie L; Chen H; Wang Y
Mol Biol (Mosk); 2023; 57(4):706-708. PubMed ID: 37528791
[TBL] [Abstract] [Full Text] [Related]
6. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
7. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits vegfr 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
[TBL] [Abstract] [Full Text] [Related]
8. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
[TBL] [Abstract] [Full Text] [Related]
9. Synthesis of Palladium-Catalysed C-C Bond Forming 5-Chloro Quinolines via Suzuki-Miyaura Coupling; Anti-pancreatic cancer Screening on PANC-1 Cell Lines.
Rahman A; Ningegowda NB; Siddappa MK; Pargi M; Kumaraswamy HM; Satyanarayan ND; Achur R
Chem Biodivers; 2023 Jan; 20(1):e202200622. PubMed ID: 36437502
[TBL] [Abstract] [Full Text] [Related]
10. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract] [Full Text] [Related]
11. Maximum Value on Arterial Phase Computed Tomography Predicts Prognosis and treatment Efficacy of Sunitinib for pancreatic Neuroendocrine Tumours.
Chen H; Li Z; Hu Y; Xu X; Ye Z; Lou X; Zhang W; Gao H; Qin Y; Zhang Y; Chen X; Chen J; Tang W; Yu X; Ji S
Ann Surg Oncol; 2023 May; 30(5):2988-2998. PubMed ID: 36310316
[TBL] [Abstract] [Full Text] [Related]
12. The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during treatment: An Imaging-Based Analysis.
Muraishi N; Kawamura Y; Akuta N; Shindoh J; Matsumura M; Okubo S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Yasuda I; Kumada H
Oncology; 2023; 101(2):134-144. PubMed ID: 36103864
[TBL] [Abstract] [Full Text] [Related]
13. Antipsychotic drugs induce vascular defects in hematopoietic organs.
Deng ZH; Zhong J; Jiang HL; Jeong HW; Chen JW; Shu YH; Tan M; Adams RH; Xie KP; Chen Q; Liu Y
FASEB J; 2022 Oct; 36(10):e22538. PubMed ID: 36065631
[TBL] [Abstract] [Full Text] [Related]
14. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
15. CircCCT3 Acts as a Sponge of miR-613 to Promote Tumor Growth of pancreatic cancer Through Regulating VEGFA/vegfr2 Signaling.
Hou JP; Men XB; Yang LY; Han EK; Han CQ; Liu LB
Balkan Med J; 2021 Jul; 38(4):229-238. PubMed ID: 34274912
[TBL] [Abstract] [Full Text] [Related]
16. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Qin S; Li Q; Gu S; Chen X; Lin L; Wang Z; Xu A; Chen X; Zhou C; Ren Z; Yang L; Xu L; Bai Y; Chen L; Li J; Pan H; Cao B; Fang W; Wu W; Wang G; Cheng Y; Yu Z; Zhu X; Jiang D; Lu Y; Wang H; Xu J; Bai L; Liu Y; Lin H; Wu C; Zhang Y; Yan P; Jin C; Zou J
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):559-568. PubMed ID: 33971141
[TBL] [Abstract] [Full Text] [Related]
17. Surufatinib: First Approval.
Syed YY
Drugs; 2021 Apr; 81(6):727-732. PubMed ID: 33788183
[TBL] [Abstract] [Full Text] [Related]
18. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.
Huang DQ; Muthiah MD; Zhou L; Jumat H; Tan WX; Lee GH; Lim SG; Kow A; Bonney G; Shridhar I; Lim YT; Wee A; Pang YH; Soon G; Chow P; Dan YY
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1313-1325. PubMed ID: 33340714
[TBL] [Abstract] [Full Text] [Related]
19. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C; Hagege A; Borchiellini D; Thamphya B; Rastoin O; Ambrosetti D; Iovanna J; Rioux-Leclercq N; Porta C; Negrier S; Ferrero JM; Chamorey E; Pagès G; Dufies M
Oncoimmunology; 2020 Nov; 9(1):1846901. PubMed ID: 33299657
[TBL] [Abstract] [Full Text] [Related]
20. Kinome Array Profiling of Patient-Derived pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases.
Creeden JF; Alganem K; Imami AS; Brunicardi FC; Liu SH; Shukla R; Tomar T; Naji F; McCullumsmith RE
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33213062
[TBL] [Abstract] [Full Text] [Related]
[Next]
